Table 3.
Radiological findings of the three groups at follow-up screening.
| HA-HA | HA-NA | NA-NA | p-Value | Adjusted p-Value | |
|---|---|---|---|---|---|
| Mean CIMT (um) |
n = 47 0.6 (0.6–0.7) |
n = 28 0.6 (0.6–0.7) |
n = 33 0.6 (0.6–0.7) |
0.93 | 0.82 |
| CACs | n = 32 | n = 18 | n = 18 | 0.32 | 0.19 |
| No CAC (0 AU) | 25 (78.1) | 15 (83.3) | 17 (94.4) | ||
| Any CAC (0–400 AU) | 7 (21.9) | 3 (16.7) | 1 (5.6) | ||
| Presence of coronary plaque |
n = 31 5 (15.6) |
0 (0.0) |
n = 18 3 (16.7) |
0.23 | 0.94 |
| Relevant CVD | 0 (0.0) | 0 (0.0) | 0 (0.0) | - | - |
HA-HA: women who were hyperandrogenic at initial screening and at follow-up screening; HA-NA: women who were hyperandrogenic at initial screening and normoandrogenic at follow-up screening; NA-NA: women with PCOS who were normoandrogenic at initial screening and at follow-up screening. Values are presented as medians (interquartile range) or as numbers (percentages). The adjusted p-value was adjusted for BMI. CIMT: carotid intima-media thickness; CACs: coronary artery calcification score; AUs: Agatston Units; and CVD: cardiovascular disease. Relevant CVD was defined as luminal stenosis of ≥50% or a CACs of ≥100 AU.